Intas Pharma launches first etanercept biosimilar
Intas Pharmaceuticals has launched INTACEPT, the first biosimilar to Amgen’s Enbrel (etanercept). INTACEPT has been launched in two strengths, 25mg in 0.5... Read More
+91 789 2456 581 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Admission
- Course Quick Glance
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Course Upgrade
- Verify Course Certificate
- Request for Course Completion Certificate
- Corporate Training
- Knowledge Base
Tag
INTACEPT
Our Popular Courses
Recent Articles
- Pharma acquisition case study: Lundbeck to acquire Alder BioPharmaceuticals for US$ 1.95 billion
- Insight on submission of USFDA sBLA of Tremfya (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA)
- Mitsubishi Tanabe Pharma, Daiichi Sankyo enters licensing agreement for ALS treatment agent edaravone in Brazil
- Alexion’s inlicensing deal for Amyloidosis Candidate In Japan
- Insight on Boehringer Ingelheim’s new indication approval for Ofev to slow the rate of decline in pulmonary function in patients with Ssc-ILD
- Sanofi India announces sale of its Ankleshwar facility to Zentiva
- What are DACH region? Which countries are part of DACH region?
- Strides Pharma acquires stake in Fairmed Healthcare for extensive growth in DACH region
- GSK to acquire Celiac-Focused Sitari Pharmaceuticals
- Takeda recalled of NATPARA (a parathyroid hormone) in US
- Sandoz to commercialize proposed multiple sclerosis biosimilar natalizumab
- Boehringer Ingelheim’s KRAS and Lupin’s MEK inhibitor compound (LNP3794) – Licensing, development and Commercialization Agreement
- Sumitomo Dainippon and Roivant’s strategic alliance to develop new medicine
- GSK, INNOVAX and Xiamen University’s Global co-developmennt alliance for cervical cancer vaccine
- Insight on USFDA approval of new add-on drug, Nourianz (istradefylline), to treat off episodes in adults with Parkinson’s disease
- Pharma brand acquisition case study: Amgen to acquire Celgene’s Otezla
- Case Study: USFDA approval of AbbVie’s RINVOQ (upadacitinib)
- GSK grants exclusive technology license for Ebola vaccines to Sabin Vaccine Institute
- Turalio: USFDA approval of first therapy for rare joint tumor
- Case Study: The Mylan-Upjohn,Pfizer Merger